Nektar Therapeutics (NKTR) concluded trading on Wednesday at a closing price of $8.61, with 0.45 million shares of worth about $3.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.17% during that period and on June 18, 2025 the price saw a loss of about -1.37%. Currently the company’s common shares owned by public are about 12.41M shares, out of which, 11.96M shares are available for trading.
Stock saw a price change of -9.84% in past 5 days and over the past one month there was a price change of -17.41%. Year-to-date (YTD), NKTR shares are showing a performance of -38.28% which decreased to -50.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.48 but also hit the highest price of $22.79 during that period. The average intraday trading volume for Nektar Therapeutics shares is 205.68K. The stock is currently trading -13.85% below its 20-day simple moving average (SMA20), while that difference is down -13.74% for SMA50 and it goes to -39.42% lower than SMA200.
The stock has a current market capitalization of $106.82M and its 3Y-monthly beta is at 0.56. It has posted earnings per share of -$9.53 in the same period. It has Quick Ratio of 3.24 while making debt-to-equity ratio of 13.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NKTR, volatility over the week remained 5.58% while standing at 9.30% over the month.
Stock’s fiscal year EPS is expected to drop by -40.83% while it is estimated to increase by 1.48% in next year. EPS is likely to shrink at an annualized rate of -16.69% for next 5-years, compared to annual growth of 25.49% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on April 11, 2025 offering a Buy rating for the stock and assigned a target price of $2 to it. Coverage by Oppenheimer stated Nektar Therapeutics (NKTR) stock as an Outperform in their note to investors on March 14, 2025, suggesting a price target of $6 for the stock. On January 08, 2025, B. Riley Securities Initiated their recommendations, while on December 10, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $6.50. Stock get an Overweight rating from Piper Sandler on November 04, 2024.
